Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization
Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024.